rhTNK-tPA

DRUG8 trials

Conditions

Acute Ischemic StrokeAcute ST Elevation Myocardial InfarctionMinor Ischemic StrokeStroke, AcuteStroke, IschemicrhTNK-tPA

Phase 2

Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

CompletedNCT04733742

Xinqiao Hospital of ChongqingStroke, Acute, Stroke, Ischemic

Start: 2022-05-09End: 2025-02-07Updated: 2025-04-03

Phase 3

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

CompletedNCT04797013

Beijing Tiantan HospitalAcute Ischemic Stroke

Start: 2021-06-12End: 2022-07-15Updated: 2023-01-17

Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ

RecruitingNCT06414499

Beijing Tiantan HospitalMinor Ischemic Stroke

Start: 2025-07-09End: 2026-10-31Target: 1386Updated: 2025-07-24

Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.

RecruitingNCT07201688

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Acute Ischemic Stroke

Start: 2025-11-30End: 2027-09-30Target: 890Updated: 2025-12-16

Phase 4

The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

CompletedNCT02835534

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Acute ST Elevation Myocardial Infarction

Start: 2016-05-31End: 2020-01-31Updated: 2022-05-25

Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window

CompletedNCT05752916

Xuanwu Hospital, BeijingAcute Ischemic Stroke

Start: 2023-06-02End: 2025-10-28Updated: 2025-12-02

Unknown Phase

INtravenous TNK for Acute isChemicsTroke in China

CompletedNCT04588337

General Hospital of Shenyang Military RegionStroke, Ischemic

Start: 2022-01-06End: 2024-04-09Updated: 2024-04-10

Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke

Not yet recruitingNCT07519889

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Acute Ischemic Stroke, rhTNK-tPA

Start: 2026-04-10End: 2027-04-10Target: 4500Updated: 2026-04-09

2025-10-271 citations

A multicenter, prospective, randomized, open-label, blinded endpoint trial of intravenous thrombolysis with tenecteplase for acute non-large vessel occlusion in extended time window (OPTION): Rationale and design.

2025-10-25

Intravenous Tenecteplase before Thrombectomy in Stroke

New England Journal of Medicine2025-05-2132 citations

Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol

Journal of the American Heart Association2024-10-225 citations

Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia

Journal of the American Heart Association2024-10-112 citations

Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: A randomized non-inferiority trial

Chinese Medical Journal2023-06-029 citations

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial

Stroke and Vascular Neurology2023-05-2914 citations

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.

2023-02-09198 citations

Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design

Stroke and Vascular Neurology2021-08-2613 citations

Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial

BMJ Open2017-09-019 citations